Lead Optimization Services in IBD Drug Discovery

Once a lead compound is identified, it must be optimized to become a drug candidate. In the IBD drug discovery process, lead compound optimization involves the synthesis and characterization of identified lead compounds, such as modifying the chemical structure of a compound or biologic to improve target specificity, selectivity, pharmacodynamics, pharmacokinetics, and toxicological properties to produce a preclinical drug candidate. Converting hits into high-quality lead series is the primary goal of hit-to-lead optimization in drug discovery.

Our Lead Optimization Services

Ace Therapeutics provides reliable lead optimization services to accelerate our clients' IBD drug development programs. Our multidisciplinary drug discovery teams ensure that structure-activity relationships (SARs) are elucidated and optimized with maximum efficiency. We pride ourselves on building interactive and highly collaborative relationships with our clients, always ensuring that we provide strategically sound and proactive solutions to advance projects.

Ace Therapeutics has extensive experience from lead optimization to preclinical selection of IBD drug candidates.

• Medicinal chemistry, artificial intelligence (AI) based optimization
• Predictive modeling using computer-aided drug design (CADD)
• Biochemical and functional potency
• Target engagement in vitro
• Selective analysis and optimization
• Potency distribution showing SAR
• Solubility analysis and optimization
• Toxicity analysis
• Absorption, distribution, metabolism and excretion (ADME)/drug metabolism and pharmacokinetics (DMPK) studies
• Mechanism of action studies
• In vivo efficacy evaluation in animal models of IBD
• Formulation studies

Our Advantages

• Through the study of pharmacokinetic parameters such as stability, bioavailability, toxicity, and efficacy, we discover higher quality lead compounds for our clients' IBD drug development projects.
• Our reliable 3D intestinal cell culture models enable more informed selection of lead candidates than ever before.
• Based on a comprehensive understanding of the pathogenesis of IBD, our team of experts continues to enhance their capabilities in toxicology screening, biomarker identification, and predictive translational models.

Ace Therapeutics' lead compound optimization services are designed to transform promising lead compounds into high-quality compounds suitable for human clinical evaluation in IBD. Our interdisciplinary team fine-tunes molecular structures to optimize novelty, efficacy, and safety, while tailoring ADME properties to achieve the right balance of exposure, duration, and target engagement. Contact us to explore how we can help accelerate your project toward clinical success.